Development of a docetaxel micellar formulation using poly(ethylene glycol)–polylactide–poly(ethylene glycol) (PEG–PLA–PEG) with successful reconstitution for tumor targeted drug delivery

Drug Delivery

Han-Gon Choi¹  Dong Shik Kim¹  Kwon-Yeon Weon²  Jin Kook Kang³  Kyung Taek Oh³  Chaemin Lim³  Taehoon Sim³  Ngoc Ha Hoang³  Jae Eun Kim³  Hyo-Kyung Han⁴  Eun Seong Lee⁵  Yu Seok Youn⁶ 

[1] College of Pharmacy & Institute of Pharmaceutical Science and Technology, Hanyang University, Ansan, Republic of Korea;College of Pharmacy, Catholic University of Daegu, Gyeongsan-si, Republic of Kore;College of Pharmacy, Chung-Ang University, Seoul, Republic of Korea;College of Pharmacy, Dongguk University-Seoul, Goyang, Republic of Korea;Department of Biotechnology, The Catholic University of Korea, Bucheon, Republic of Korea;School of Pharmacy, SungKyunKwan University, Suwon City, Republic of Korea;

关键词: Nanomedicine;    lyophilization;    cancer;    reconstitution;    polymeric micelle;   

DOI  :  10.1080/10717544.2018.1477865

来源: publisher

【 摘 要 】

Docetaxel (DTX)-loaded polymeric micelles (DTBM) were formulated using the triblock copolymer, poly(ethylene glycol)–polylactide–poly(ethylene glycol) (PEG–PLA–PEG), to comprehensively study their pharmaceutical application as anticancer nanomedicine. DTBM showed a stable formulation of anticancer nanomedicine that could be reconstituted after lyophilization (DTBM-R) in the presence of PEG 2000 and D-mannitol (Man) as surfactant and protectant, respectively. DTBM-R showed a particle size less than 150 nm and greater than 90% of DTX recovery after reconstitution. The robustly formed micelles might minimize systemic toxicity due to their sustained drug release and also maximize antitumor efficacy through increased accumulation and release of DTX from the micelles. From the pharmaceutical development point of view, DTBM-R showing successful reconstitution could be considered as a potent nanomedicine for tumor treatment.

【 授权许可】

CC BY